Mr Prashanth Nagre, CEO, Fermenta Biotech
In Biotechnology space where the FBL is placed, we see a positive transformation towards changing various chemical processes into enzyme mediated process.
Already, there have been commercial success stories of using next generation enzymes in the synthesis of antibiotics and we expect the trend to go beyond antibiotics. With few blockbuster molecules which are prepared using an enzymatic approach, going off patent, we anticipate many companies would commit into this space.
The year 2014 has been with mixed response, in some segments we have seen a very positive response but in some we have seen stiff competition. We believe competition makes one better and hones the overall organization skills.
With the positive and emerging trend of "green" manufacturing practice, FBL is poised for a leadership position in the enzyme biotechnology space, by offering next generation enzyme, diversity of enzyme application and integrating key processes. Our company's focus would be overall, spanning all the areas. As FBL would be expanding in regulatory landscape for new products, the core focus would be quality and regulatory compliance across all the market segments.
FBL being a pioneer in enzymatics, is committed to offer value addition and create niche space for its products and technologies. The industry so far has been responding well inspite of sheer competition from within and China. But there is a space for quality and value added services. So, the key is to strive on the quality, cost and novelty in providing overall value addition.
Overall lifescience sector is expected to perform better with more new companies and technologies engaged to create value. The off patent status of few molecules is expected to drive the growth in this segment. Clinical services sector as a combination with other value added services is expected to perform better amidst challenging business environment.